Epithelial cell derived Thymic Stromal Lymphopoietin (TSLP) instructs dendritic cells (DCs) via the expression of OX40L to induce Th2. TSLP and OX40L are therefore promising targets for the development of new therapies for allergic asthma. The aim of this project is to study the potential of targeting human TSLP and human OX40L for intervening with the initiation and/or progression of allergic asthma, in a humanized mouse model.